{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:12:48Z","timestamp":1786119168296,"version":"build-2736575974"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1097\/cco.0b013e3282f0e20c","type":"journal-article","created":{"date-parts":[[2009,3,4]],"date-time":"2009-03-04T18:40:40Z","timestamp":1236192040000},"page":"628-634","source":"Crossref","is-referenced-by-count":6,"title":["Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders"],"prefix":"10.1097","volume":"19","author":[{"given":"Yana","family":"Pikman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross L","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210128","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"R2-16-20210128","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1073\/pnas.58.4.1468","article-title":"Clonal origin of chronic myelocytic leukemia in man","volume":"58","author":"Fialkow","year":"1967","journal-title":"Proc Natl Acad Sci USA"},{"key":"R3-16-20210128","doi-asserted-by":"crossref","first-page":"6848","DOI":"10.1073\/pnas.88.15.6848","article-title":"Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction","volume":"88","author":"Gilliland","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"R4-16-20210128","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM197610212951702","article-title":"Polycythemia vera: stem-cell and probable clonal origin of the disease","volume":"295","author":"Adamson","year":"1976","journal-title":"N Engl J Med"},{"key":"R5-16-20210128","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","volume":"306","author":"Bartram","year":"1983","journal-title":"Nature"},{"key":"R6-16-20210128","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukaemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"R7-16-20210128","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinas on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"R8-16-20210128","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation","volume":"77","author":"Golub","year":"1994","journal-title":"Cell"},{"key":"R9-16-20210128","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/hmg\/11.12.1391","article-title":"The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA","volume":"11","author":"Baxter","year":"2002","journal-title":"Hum Mol Genet"},{"key":"R10-16-20210128","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.278.5341.1309","article-title":"A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia","volume":"278","author":"Lacronique","year":"1997","journal-title":"Science"},{"key":"R11-16-20210128","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood.V90.7.2535","article-title":"Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia","volume":"90","author":"Peeters","year":"1997","journal-title":"Blood"},{"key":"R12-16-20210128","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"R13-16-20210128","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"key":"R14-16-20210128","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-KIT resistant to imatinib are sensitive to the tyrosine kinase inhibitor PKC412","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"},{"key":"R15-16-20210128","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"R16-16-20210128","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"R17-16-20210128","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"R18-16-20210128","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"R19-16-20210128","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"R20-16-20210128","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"R21-16-20210128","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an Acquired JAK2 Mutation in Polycythemia Vera","volume":"280","author":"Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"R22-16-20210128","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2006-03-007146","article-title":"Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis","volume":"109","author":"Delhommeau","year":"2007","journal-title":"Blood"},{"key":"R23-16-20210128","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2006-04-017392","article-title":"Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera","volume":"108","author":"Ishii","year":"2006","journal-title":"Blood"},{"key":"R24-16-20210128","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"R25-16-20210128","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM197610212951702","article-title":"Polycythemia vera; stem cell and probable clonal origin of the disease","volume":"295","author":"Adamson","year":"1976","journal-title":"N Engl J Med"},{"key":"R26-16-20210128","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","article-title":"X-inactivation based clonality analysis and quantitative JAK2V617F assessment reveals a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F negative ET and MMM patients with clonal hematopoiesis","volume":"107","author":"Levine","year":"2006","journal-title":"Blood"},{"key":"R27-16-20210128","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"R28-16-20210128","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","article-title":"JAK2 mutation 1849G >T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia","volume":"106","author":"Jelinek","year":"2005","journal-title":"Blood"},{"key":"R29-16-20210128","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood-2006-02-005751","article-title":"Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation","volume":"108","author":"Szpurka","year":"2006","journal-title":"Blood"},{"key":"R30-16-20210128","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.leu.2404036","article-title":"Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma","volume":"20","author":"Melzner","year":"2006","journal-title":"Leukemia"},{"key":"R31-16-20210128","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.leu.2404206","article-title":"JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained","volume":"20","author":"Steensma","year":"2006","journal-title":"Leukemia"},{"key":"R32-16-20210128","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/blood-2005-09-3644","article-title":"Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7","volume":"107","author":"Frohling","year":"2006","journal-title":"Blood"},{"key":"R33-16-20210128","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/sj.onc.1209163","article-title":"The JAK2 V617F mutation in de novo acute myelogenous leukemias","volume":"25","author":"Lee","year":"2006","journal-title":"Oncogene"},{"key":"R34-16-20210128","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","article-title":"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia","volume":"106","author":"Levine","year":"2005","journal-title":"Blood"},{"key":"R35-16-20210128","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2005-05-2087","article-title":"The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders","volume":"106","author":"Scott","year":"2005","journal-title":"Blood"},{"key":"R36-16-20210128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0301-472X(01)00789-5","article-title":"Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera","volume":"30","author":"Kralovics","year":"2002","journal-title":"Exp Hematol"},{"key":"R37-16-20210128","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood-2006-04-018259","article-title":"Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia","volume":"108","author":"Scott","year":"2006","journal-title":"Blood"},{"key":"R38-16-20210128","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"key":"R39-16-20210128","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"R40-16-20210128","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"R41-16-20210128","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","article-title":"V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis","volume":"107","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"R42-16-20210128","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation","volume":"102","author":"Lu","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"R43-16-20210128","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1038\/sj.onc.1206381","article-title":"Differential regulation of SOCS genes in normal and transformed erythroid cells","volume":"22","author":"Sarna","year":"2003","journal-title":"Oncogene"},{"key":"R44-16-20210128","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/sj.leu.2404322","article-title":"Suppressor of cytokine signaling-3 is overexpressed in erythroid precursors of myelodysplastic syndrome","volume":"20","author":"Baker","year":"2006","journal-title":"Leukemia"},{"key":"R45-16-20210128","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1182\/blood-2006-08-039735","article-title":"The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3","volume":"109","author":"Hookham","year":"2007","journal-title":"Blood"},{"key":"R46-16-20210128","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"key":"R47-16-20210128","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1371\/journal.pone.0000018","article-title":"Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F","volume":"1","author":"Zaleskas","year":"2006","journal-title":"PLoS ONE"},{"key":"R48-16-20210128","doi-asserted-by":"crossref","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-06-2210","article-title":"Characterization of murine JAK2V617F-positive myeloproliferative disease","volume":"66","author":"Bumm","year":"2006","journal-title":"Cancer Res"},{"key":"R49-16-20210128","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"key":"R50-16-20210128","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"R51-16-20210128","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"R52-16-20210128","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"R53-16-20210128","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2005-12-4852","article-title":"Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders","volume":"108","author":"Bellanne-Chantelot","year":"2006","journal-title":"Blood"},{"key":"R54-16-20210128","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1182\/blood-2005-12-4988","article-title":"Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders","volume":"107","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"R55-16-20210128","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2005-11-009605","article-title":"Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders","volume":"108","author":"Kralovics","year":"2006","journal-title":"Blood"},{"key":"R56-16-20210128","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2-V617F positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"key":"R57-16-20210128","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1182\/blood.V108.11.3594.3594","article-title":"CEP-701 is a JAK2 inhibitor which attenuates JAK2\/STAT5 signaling pathway and the proliferation of primary cells from patients with myeloproliferative disorders [abstract]","volume":"108","author":"Dobrzanski","year":"2006","journal-title":"Blood"},{"key":"R58-16-20210128","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood.V108.11.3616.3616","article-title":"Inhibition of JAK2 V617F-induced erythroid skewing of hematopoietic stem cell differentiation with a selective JAK2 antagonist [abstract]","volume":"108","author":"Geron","year":"2006","journal-title":"Blood"},{"key":"R61-16-20210128","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.leu.2404750","article-title":"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L\/K mutations","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"R62-16-20210128","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"key":"R63-16-20210128","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/377065a0","article-title":"Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)","volume":"377","author":"Macchi","year":"1995","journal-title":"Nature"},{"key":"R64-16-20210128","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1182\/blood-2003-06-1856","article-title":"Allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"102","author":"Deeg","year":"2003","journal-title":"Blood"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e3282f0e20c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:42:56Z","timestamp":1786038176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-200711000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e3282f0e20c","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}